Title:Major Highlights of the CAR-TCR Summit, Boston, 2016
Volume: 17
Issue: 10
Author(s): Vita Golubovskaya*, Robert Berahovich, Shirley Xu, Hizkia Harto and Lijun Wu*
Affiliation:
- Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806,United States
- Promab Biotechnologies, 2600 Hilltop Drive, Richmond, CA, 94806,United States
Keywords:
Chimeric antigen receptor, immunotherapy, cytokine, cancer, tumor antigen, T-cell enginering.
Abstract: Cellular immunotherapies such as CAR-T cell therapy and TCR-T cell therapy are relatively new,
highly promising approaches for the treatment of cancer. In CAR-T cell therapy, a patient's T cells are engineered
to express chimeric antigen receptors targeting tumor-associated cell surface antigens. In TCR-T cell therapy, the
patient's T cells are engineered to express receptors targeting intracellular antigens. This report will summarize
presentations from the recent CAR-TCR summit in Boston on September 13-16, 2016. These presentations were
given by leaders in the field and many were divided into three streams: Discovery and Genetic T Cell
Engineering; Translation and Clinical Development; and Manufacturing, Supply Chain and Commercialization.
The report summarizes major pharmaceutical companies developing these novel therapies and provides
challenges and perspectives for future therapeutic developments.
